Decision on IPR:
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
Status
|
|
IPR2016-00408
&
IPR2016-00409
|
12/29/2015
|
07/07/2016
|
Boehringer Ingelheim GmbH
|
8,889,135
|
AbbVie Biotechnology Ltd.
|
Final Written Decision - Jul 6,
2017
(Claims 1-5 are unpatentable)
|
The ’135 patent,
titled “Methods of Administering Anti-TNFα Antibodies,” issued on November 18,
2014. The ’135 patent discloses methods of treating rheumatoid arthritis (“RA”)
with a human anti-tumor necrosis factor α (“TNFα”) antibody.
No comments:
Post a Comment